ERBB2 and breast carcinoma: Neratinib is approved in the USA for the extended adjuvant treatment of early-stage HER2-positive breast cancer after standard trastuzumab-based adjuvant therapy based on findings from the ExteNET (Extended Adjuvant Treatment of Breast Cancer with Neratinib) trial.